肌少症对头颈癌同步放化疗耐受性与结局的影响
多因素分析显示肌少症与化疗毒性(HR 2.15,p=0.01)和放疗中断延长(HR 2.99,p=0.04)相关,并与更差的总生存(HR 1.83,p=0.03)和无进展生存(HR 1.65,p=0.03)相关;但在p16阳性口咽癌中未见此关联。
要点
- 肌少症患者同步放化疗时更易出现化疗毒性和放疗中断。
- 肌少症与头颈癌总生存和无进展生存更差相关。
- p16阳性口咽癌中肌少症与结局无关。
核心结论
- 肌少症患者接受同步放化疗更可能需要放疗中断并出现化疗毒性,可能贡献于头颈癌更差的生存结局,但p16阳性口咽癌除外。
主要发现
- 多因素分析中,同步吸烟(HR 3.85,p<0.01)和肌少症(HR 2.15,p=0.01)与化疗毒性相关。
- 年龄>65岁(HR 2.94,p<0.01)和肌少症(HR 2.99,p=0.04)与放疗中断延长相关。
- 肌少症与更差的总生存(HR 1.83,p=0.03)和无进展生存(HR 1.65,p=0.03)相关。
- 在p16阳性口咽癌中单独分析时,肌少症与结局无关。
临床怎么用
- 对头颈癌同步放化疗患者,可基于放疗计划CT的C3椎体肌肉评估肌少症以识别治疗耐受性差的高危人群。
- 肌少症患者需加强化疗毒性监测和放疗中断风险管理,但p16阳性口咽癌患者可能不适用此风险分层。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Sarcopenia is a predictor of poor prognosis in cancer patients. One potential mechanism for worse outcomes in sarcopenic patients is worse tolerance to treatment; this has not been investigated with regard to radiation treatment. We reviewed our institutional experience of head and neck cancer patients receiving concurrent chemoradiation and assessed outcomes with respect to sarcopenia. MATERIALS AND METHODS: Patients treated between 2012 and 2016 were reviewed. Sarcopenia was assessed from radiation planning computed tomography (CT) scans using muscles at the C3 vertebral body using previously published methods. Survival was calculated using the Kaplan-Meier method. Association between patient factors and outcome was calculated in univariate and multivariate analyses. RESULTS: Two hundred and forty-six patients were included. Fifty-eight percent met criteria for sarcopenia. Thirty-seven percent experienced chemotherapy delays of >1 week and 14% had radiation treatment breaks >1 week. On multivariate analysis, concurrent smoking (HR 3.85, p < 0.01) and sarcopenia (HR 2.15, p = 0.01) were associated with chemotherapy toxicity and age >65 years (HR 2.94, p < 0.01) and sarcopenia (HR 2.99, p = 0.04) were associated with prolonged radiation breaks. Sarcopenia was associated with worse overall survival (HR 1.83, p = 0.03) and progression-free survival (HR 1.65, p = 0.03) in the overall cohort. When analyzed separately, sarcopenia was not associated with outcomes in p16-positive oropharynx cancers. CONCLUSION: Sarcopenic patients receiving concurrent chemoradiation are more likely to require radiation treatment breaks and suffer chemotherapy toxicity than their non-sarcopenic counterparts. This may contribute to worse survival outcomes in head and neck cancer, with the exception of p16-positive oropharyngeal cancer.
引用
- Ganju RG, Morse R, Hoover A, et al. The impact of sarcopenia on tolerance of radiation and outcome in patients with head and neck cancer receiving chemoradiation. Radiother Oncol. 2019. PMID: 31085391. doi:10.1016/j.radonc.2019.04.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。